赵勤俭

博士，教授，博士生导师，公共卫生学院副院长
国家特聘专家
通信地址：厦门大学翔安校区椭圆楼305
邮编：361102
电话：
电子邮箱：qinjian_zhao@xmu.edu.cn

教育经历：
(1) 1981.9–1986.7, 北京医科大学, 药物化学, 学士
(2) 1986.9–1989.7, 北京医科大学, 药物化学, 硕士
(3) 1989.9–1993.11, 美国天主教大学, 生物有机化学, 博士


工作经历：
(1) 2015.10-至今, 厦门大学, 公共卫生学院, ****，公共卫生学院副院长
(2) 2011.6-2015.10, 厦门大学, 公共卫生学院, ****
(3) 1997.7-2011.6, 美国默克公司研发部, 生物化学研究者、研究员、高级研究员、杰出高级研究员/科学主任
(4) 1993.11-1997.6, 约翰?霍普金斯大学医学院，药理与分子科学系及生物化学系，博士后


学术简介：
赵勤俭老师自1997年起在世界著名药企默克公司从事生物药物相关的研制工作。在疫苗、治疗性蛋白的研发和生产中建立了多种关键的研究工具和质控手段。作为主要成员参与了世界第一个癌症疫苗（宫颈癌疫苗，Gardasil?）的研制全过程，负责其中部分关键工艺的研发及产品的质量控制。2011年起作为****全职担任厦门大学公共卫生学院教授、博导，主要从事生物大分子药物质量分析与新型佐剂方面的研究，其优化后的铝佐剂现已成功应用于实验室自主研发的戊型肝炎疫苗（已上市）及HPV16/18 双价苗（已获批上市）等国产疫苗中。由其主导研发的新型双膦酸佐剂已申请4项专利，并已将其应用到重组新冠疫苗研发当中，目前正在临床前研究阶段。学术方面，在PNAS、Trends in Biotechnology、Expert Review of Vaccines等国际知名期刊共发表100余篇学术论文，其中第一作者、共第一作者或通讯作者70余篇；申请专利7项，并担任多个知名疫苗专业期刊杂志编委（npj vaccines、Human Vaccines & Immunotherapeutics）。


研究领域：
（1）生物大分子药物及疫苗制剂的质量分析
重组类病毒颗粒（virus-like particles, VLPs）
表位鉴定（Epitope identification）
体外相对效力分析（in vitro relative potency, IVRP）
（2）新型疫苗佐剂研究
佐剂制备、理化性质鉴定
佐剂安全性、有效性评估
疫苗佐剂免疫调节机制



主持课题：
1.国家自然科学基金面上项目，**，基于矿化双膦酸微纳米颗粒的新型佐剂免疫作用机制研究，2021/01-2024/12，58万，在研，主持
2.国家自然科学基金重点项目，**，多聚化抗原诱导高效体液免疫应答的机制研究，2018/01-2022/12，250万，在研，参与（核心骨干成员）
3. 国家自然科学基金面上项目，**，植物源多糖及寡糖引发平衡的Th1/Th2类免疫反应机制研究，2017/01-2020/12，60万，已结题，主持
4. 国家自然科学基金面上项目，**，人乳头瘤病毒样颗粒不同中和表位的特性与结构基础研究，2015/01-2018/12，72万，已结题，主持
5. 国家自然科学基金面上项目，**，人乳头瘤病毒样颗粒表位的鉴定和中和机制研究，2013/01-2013/12，16万，已结题，主持
6. “十二五”863 重大项目，2012AA02A408，疫苗研发关键技术及产品研发，2012/01-2015/12，1600万元，已结题，主持


获得荣誉：
1.全国抗击新冠肺炎疫情先进集体奖（厦门大学国家传染病诊断试剂与疫苗工程技术研究中心），授予单位：中共中央、国务院、中央军委，2020年9月
2.求是杰出科技成就集体奖，香港求是科技基金会，国际学术奖，2015年9月（夏宁邵，李少伟，张军，吴婷，黄守杰，李益民，葛胜祥，顾颖，郑子峥，袁权，潘晖榕，吴文翰，赵勤俭，史维国，罗文新，陈毅歆，程通，俞海）
3.荣获“工业生物技术奖”，授予单位：美国化学学会生物化学技术部，2006年9月


近五年代表性论文（第一作者或通讯作者）：
1.Bin He, Zhigang Zhang, Xinyuan Zhang, Ziming Tang, Chang Liu, Zizheng Zheng, Shaowei Li, Jun Zhang, Ningshao Xia, Qinjian Zhao*. Functional epitopes on hepatitis E virions and recombinant capsids are highly comformation-dependent. Human Vaccines & Immunotherapeutics. 2020, 16(7):1554-1564.
2.Yike Li, Xiaofen Huang, Zhigang Zhang, Shaowei Li, Jun Zhang, Ningshao Xia, Qinjian Zhao*. Prophylactic hepatitis E vaccines: antigenic analysis and serological evaluation. Viruses. 2020, 12(1):109.
3.Xiao Zhang, Bingchun Zhao, Mingmei Ding, Shuo Song, Yinfeng Kang, Yang Yu, Miao Xu, Tong Xiang, Ling Gao, Qisheng Feng, Qinjian Zhao*, Mu-Sheng Zeng*, Claude Krummenacher, Yi-Xin Zeng*. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics. 2020, 10(13): 5704-5718.
4.Xiaochen Yin, Xin Wang, Zhigang Zhang, Yufang Li, Zhijie Lin, Huirong Pan, Ying Gu, Shaowei Li, Jun Zhang, Ningshao Xia*, Qinjian Zhao*. Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods. Journal of Pharmaceutical and Biomedical Analysis. 2020, 177:112880.
5.Zhigang Zhang, Tianying Zhang, Lu Cao, Xin Wang, Jiali Cao, Xiaofen Huang, Yashuang Cai, Zhijie Lin, Huirong Pan, Quan Yuan, Mujin Fang, Shaowei Li, Jun Zhang, Ningshao Xia, Qinjian Zhao*. Simultaneous in situ visualization and quantitation of dual antigens adsorbed on adjuvants using high content analysis. Nanomedicine. 2019, 14(19):2535-2548.
6.Siyi Chen, Xiaofen Huang, Yike Li, Xin Wang, Huirong Pan, Zhijie Lin, Qingbing Zheng, Shaowei Li, Jun Zhang, Ningshao Xia*, Qinjian Zhao*. Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal. European Journal of Pharmaceutics and Biopharmaceutics. 2019, 141:221-231.
7.Kaihang Wang?, Lizhi Zhou?, Xiao Zhang?, Cuiling Song?, Tingting Chen?, Jiajia Li?, Minghua Zheng?, Yingbin Wang, Qingbing Zheng?, Zizheng Zheng?, Hai Yu?, Ting Wu?, Ying Gu, Jun Zhang?, Qinjian Zhao?*, Shaowei Li??*, Ningshao Xia. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A. Antiviral Research. 2019, 164:154-161.
8.Xin Wang, Min Li, Zhijie Lin, Huirong Pan, Zimin Tang, Zizheng Zheng, Shaowei Li, Jun Zhang, Ningshao Xia*, Qinjian Zhao*. Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine. Vaccine. 2018, 36(50):7650-7658.
9.Cai Zhang, Xiaofen Huang, Siyi Chen, Yike Li, Yufang Li, Xin Wang, Jixian Tang, Lin Xia, Zhijie Lin, Wenxin Luo, Tingdong Li, Shaowei Li, Jun Zhang, Ningshao Xia*, Qinjian Zhao*. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. Vaccine. 2018, 36(45):6761-6771.
10.Zhigang Zhang, Jun Zhang, Ningshao Xia, Qinjian Zhao*. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. Human Vaccines & Immunotherapeutics. 2017, 13(10):2280-2291.
11.Xin Wang, Zhiqiang An, Wenxin Luo, Ningshao Xia, Qinjian Zhao*. Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein & Cell. 2017. 9(1):74–85.
12.Yahua Lin, Xin Wang, Xiaofen Huang, Jun Zhang, Ningshao Xia, Qinjian Zhao*. Calcium phosphate nanoparticles as a new generation vaccine adjuvant. Expert Review of Vaccines. 2017, 16(9):895-906.
13.Xiaofen Huang, Xin Wang, Jun Zhang, Ningshao Xia, Qinjian Zhao*. Escherichia coli-derived virus-like particles in vaccine development. npj Vaccines. 2017: 3.
14.Zhang X, Wei M, Sun G, Wang X, Li M, Lin Z, Li Z, Li Y, Fang M, Zhang J, Li S, Xia N*, Zhao Q*. Vaccine. Real-time stability of a hepatitis E vaccine (Hecolin?) demonstrated with potency assays and multifaceted physicochemical methods. Vaccine, 2016, 34(48):5871-5877.
15.Qinjian Zhao*, Ningshao Xia*. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure. Sci China Life Sci. 2016, DOI: 10.1007/s11427-016-0313-9
16.Lu Cao, Xin Wang, Mujin Fang, Ningshao Xia, Qinjian Zhao*. Detection of subtle differences in analogous viral capsid proteins by allowing unrestricted specific interaction in solution competition ELISA. Journal of Virological Methods, 2016, 236: 1-4.
17.Min Li, Xin Wang, Lu Cao, Zhijie Lin, Minxi Wei, Mujin Fang, Shaowei Li, Jun Zhang, Ningshao Xia*, Qinjian Zhao*. Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants. Vaccine, 2016, 34(37): 4422-4428.
18.Qingshan Lin, Kunyu Yang, Fangping He, Jie Jiang, Tingting Li, Zhenqin Chen, Rui Li, Yixin Chen, Shaowei Li*, Qinjian Zhao*, Ningshao Xia. Production of Influenza Virus HA1 Harboring Native-Like Epitopes by Pichia pastoris. Applied Biochemistry and Biotechnology, 2016, 179(7): 1275–1289.
19.Lin Xia#, Yangfei Xian#, Daning Wang, Yuanzhi Chen, Xiaofen Huang, Xingjian Bi, Hai Yu, Zheng Fu, Xinlin Liu, Shaowei Li, Zhiqiang An, Wenxin Luo*, Qinjian Zhao*, Ningshao Xia. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Scientific Report, 2016, 6: 19042.
20.Xiao Zhang, Shaowei Li, Yorgo Modis, Zhihai Li, Jun Zhang, Ningshao Xia*, Qinjian Zhao*. Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Review in Medical Virology, 2016, 26:115-128.
21.Xin Wang, Min Li, Shaowei Li, Ting Wu, Jun Zhang, Ningshao Xia*, Qinjian Zhao*. Prophylaxis against Hepatitis E: at risk populations and human vaccines. Expert review of vaccines, 2016, 15(7): 815-827.